1. Valutazione economica di voriconazolo versus amfotericina B convenzionale nel trattamento di prima linea dell’aspergillosi nei pazienti immunocompromessi
- Author
-
G. Pizzarelli and Roberto Ravasio
- Subjects
Voriconazole ,medicine.medical_specialty ,Pediatrics ,business.industry ,Health Policy ,Aspergillosis ,medicine.disease ,National health service ,Surgery ,Clinical trial ,Amphotericin B ,Life years gained ,Medicine ,Pharmacology (medical) ,Primary treatment ,business ,Medical costs ,medicine.drug - Abstract
The objective of this study was to evaluate the cost-effectiveness of voriconazole versus amphotericin B as primary therapy for immunocompromised patients with aspergillosis. We used a pre-existent model in which two cohorts of patients received voriconazole or amphotericin B. The patients were followed for 12 weeks. The analysis was conducted from the perspective of the Italian National Health Service. We considered life years gained (LYG) and direct medical costs. LYG were based on the results of an international clinical trial and direct medical costs were based on Italian treatment patterns. Benefits were discounted at 3%. Sensitivity analysis on key clinical and economic parameters were performed. LYG with voriconazole compared with amphotericin B were respectively 13,87 and 11,36 years. The expected cost was € 25.366 with voriconazole and € 26.218 with amphotericin B. This cost-effectiveness analysis suggests that voriconazole is a dominant strategy compared with amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
- Published
- 2006